This Drug Discovery Stock Is Leading the Charge In Bringing AI to Healthcare. But Is It a Buy?

Veeva Systems (NYSE: VEEV) ticks a lot of the boxes that successful growth-seeking investors tend to look for. It boasts a dominant market position, it realizes recurring revenue from sticky subscription services, and it's exposed to the artificial intelligence (AI) megatrend that's reshaping healthcare.For over a decade, Veeva Systems has been building the connective tissue that drugmakers will need to integrate AI into their drug discovery pipelines. Unfortunately for new investors, Veeva's prescient positioning isn't a secret. The stock has been trading at a steep valuation.Let's take a closer look at the biopharmaceutical industry's favorite software vendor to see if its shares are a smart buy at recent prices.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool